Velkommen til Dansk Lungemedicinsk Selskab
Dansk Lungemedicinsk Selskab formål er at arbejde for optimal behandling, forebyggelse og forskning blandt mennesker med lungesygdomme. Dette opnås ved at sikre kvalitet i uddannelse, forskning, samarbejde og tværfaglighed.
Dansk Lungemedicinsk Selskab har repræsentanter i Danmarks Lungeforening og indgår i Dansk Selskab for Intern Medicin (DSIM) samt European Respiratory Society.
Dansk Lungemedicinsk Selskab har mere end 10 stående udvalg indenfor f.eks. telemedicin, retningslinjer m.m. og deltager med repræsentanter i forskellige udvalg under Sundhedsstyrelsen. Foreningen af Yngre Lungemediciner, som repræsenterer næste generation af lungemedicinske speciallæge, er organiseret under Dansk Lungemedicinsk Selskab.
Dansk Lungemedicinsk Selskab er det faglige selskab for dig, som vil skabe bedre vilkår for vore lungepatienter nu og i fremtiden.
Næste Årsmøde: 23-24. november, 2018. Kongres- og kulturhus Odeon, Odense
Emner: Avanceret emfysembehandling, Diseases of the pleura: infections and recurrent pleural effusions, Klagesager, Rehabilitering hos kronisk lungesyge, Differentialdiagnostiske undersøgelser ved mistanke om astm
- Kategori: Professorens hjørne
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Professor: Venerino Poletti
Artikel link | DOI | PubMed | Journal: N Engl J Med I Dato: 2018 April
Kommentar til artiklen:
Immune check points are key elements in lung cancer pathogenesis. The expression on tumor cells programmed death ligand 1 (PD-L1) of 50% or greater has been shown to be associated with a significant response to pembrolizumab, an inhibitor of this pathway. In this double-blind, phase 3 trial 616 patients with metastatic nonsquamous NSCLC without sensitizing EGFR or ALK mutations were randomized to receive pemetrexed and a platinum-based drug plus either 200 mg of pembrolizumab or placebo. Improvement in overall survival and progression-free survival was seen across all PD-L1 categories. The use of immune check point inhibitors is appearing as a first line treatment approach in patients with lung nonsquamous NSCLC regardless of the PD-L1 expression.
First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial.
In this double-blind, phase 3 trial, we randomly assigned (in a 2:1 ratio) 616 patients with metastatic nonsquamous NSCLC without sensitizing EGFR or ALK mutations who had received no previous treatment for metastatic disease to receive pemetrexed and a platinum-based drug plus either 200 mg of pembrolizumab or placebo every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up to a total of 35 cycles plus pemetrexed maintenance therapy. Crossover to pembrolizumab monotherapy was permitted among the patients in the placebo-combination group who had verified disease progression. The primary end points were overall survival and progression-free survival, as assessed by blinded, independent central radiologic review.
After a median follow-up of 10.5 months, the estimated rate of overall survival at 12 months was 69.2% (95% confidence interval [CI], 64.1 to 73.8) in the pembrolizumab-combination group versus 49.4% (95% CI, 42.1 to 56.2) in the placebo-combination group (hazard ratio for death, 0.49; 95% CI, 0.38 to 0.64; P<0.001). Improvement in overall survival was seen across all PD-L1 categories that were evaluated. Median progression-free survival was 8.8 months (95% CI, 7.6 to 9.2) in the pembrolizumab-combination group and 4.9 months (95% CI, 4.7 to 5.5) in the placebo-combination group (hazard ratio for disease progression or death, 0.52; 95% CI, 0.43 to 0.64; P<0.001). Adverse events of grade 3 or higher occurred in 67.2% of the patients in the pembrolizumab-combination group and in 65.8% of those in the placebo-combination group.
In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck; KEYNOTE-189 ClinicalTrials.gov number, NCT02578680.)